Efficacy and safety evaluation test for skin health improvement of lactic acid bacteria fermented unfermented embryo extract (containing GABA)

Not Applicable

Recruiting

• Conditions: Diseases of the skin and subcutaneous tissue

• Registration Number: KCT0007565
• Lead Sponsor: mariedm

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 September 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1) Korean adults aged 30 to 60 years
2) Those with dry facial skin characteristics as a result of the skin characteristics survey
3) Those with wrinkles around the eyes (visual evaluation grade 3 or higher)
4) A person who has fully explained the purpose and content of the test and voluntarily signed the consent form to participate in the test
5) A healthy person without acute or chronic physical disease including skin disease

Exclusion Criteria

1) Women who are pregnant, lactating, or planning to become pregnant within 6 months
2) Women taking oral contraceptives
3) Those with psychiatric or skin diseases
4) Those with chronic wasting diseases such as asthma, diabetes, high blood pressure, etc.
5) Those with skin abnormalities such as spots, acne, erythema, and capillary dilatation at the test site
6) Those who have used steroid-containing skin exfoliants for more than 1 month for the treatment of skin diseases
7) Those with sensitive, hypersensitive skin
8) Those who have not passed 6 months after participating in the same exam
9) Those who have used the same or similar cosmetics or medicines on the test site within 3 months before the start of the test
10) Those who have received chemical or physical treatment (plastic, dermabrasion, laser, surgery, etc.) on the test site within 6 months before the start of the test
11) Those who are outside the upper limit of each item in the diagnosis of blood test
12) Those who have a specific allergic reaction to food
13) Persons who are executives and employees of this clinical research institute
14) Those who have had a drug-sensitive reaction or allergic reaction
15) Those with cardiovascular disease, endocrine system disease, digestive system disease, urinary system disease
16) Others who are judged to be difficult to perform according to the judgment of the investigator

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eye wrinkles evaluation, elasticity evaluation, dermal density evaluation, skin moisture content evaluation, transdermal moisture loss (TEWL) evaluation, skin desquamer evaluation, skin roughness evaluation

Secondary Outcome Measures

Name	Time	Method
Adverse reaction ;Clinical pathology test (blood)